INSILICO (03696) saw its shares rise nearly 4% during the trading session. At the time of writing, the stock was up 2.33% to HK$65.8, with a turnover of HK$61.3974 million.

The move follows the company's recent announcement of a collaboration with Google Cloud, aimed at accelerating its drug discovery processes. Through this partnership, INSILICO plans to integrate its proprietary Pharma.AI platform with Google Cloud's scalable computing infrastructure and advanced AI capabilities to enhance the speed and efficiency of its drug discovery workflow.

Specifically, INSILICO intends to incorporate the Gemini Enterprise Agent Platform and Google's Gemini series of models into its product ecosystem. This includes integrating Gemini with the company's latest tool, PandaClaw, to further strengthen target discovery and core R&D processes.

The collaboration is also expected to accelerate the development of INSILICO's internal AI agent tools and support the advancement of its broader drug development projects.